ClinicalTrials.gg
RecruitingNCT07714525Updated Jul 27, 2026

Triamcinolone Nanocapsules After Endoscopic Nasal Surgery

A Phase 2 interventional study of Triamcinolone Acetonide-Loaded Polymeric Nanocapsules and Normal Saline Nasal Irrigation in Chronic Rhinosinusitis (CRS), Nasal Polyps and Postoperative Healing After Endoscopic Nasal Surgery, sponsored by Deraya University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Deraya University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Nasal Polyps with a site in Egypt — 2 open to participants now, 2 under way, none of them phase 3. Nasal Polyps · Egypt.

Planned enrollment
7th of 10
50 · median 60
Started
2026
the only one that year
Phase 2
Only one
of the 11
Registered
11th of 11
by date
Lead sponsor
1 of 11
Deraya University

Among the 11 studies in Nasal Polyps with a site in Egypt, this one is the 7th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2026, is the only one in phase 2, and was the 11th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

2 of the 11 studies in Nasal Polyps with a site in Egypt are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Nasal Polyps with a site in Egypt, or all of them as a file.
02

Study summary

This randomised, single-masked, parallel-group clinical trial will evaluate the efficacy and safety of a topical triamcinolone acetonide-loaded polymeric nanocapsule formulation for postoperative care following endoscopic nasal surgery.

Participants will receive either the investigational triamcinolone acetonide-loaded nanocapsule formulation or standard normal saline nasal irrigation. Postoperative nasal healing, inflammation, patient-reported sinonasal symptoms, postoperative complications, and corticosteroid-related adverse effects will be compared between the two groups.

Read the detailed description

Postoperative care following functional endoscopic sinus surgery and other endoscopic nasal procedures is important for reducing inflammation, supporting mucosal healing, and preventing complications and disease recurrence.

Conventional topical nasal treatments may be rapidly cleared from the nasal cavity, which may reduce their contact time with the postoperative nasal mucosa.

The investigational formulation contains triamcinolone acetonide incorporated into polymeric nanocapsules prepared using a nanoprecipitation method. The nanocapsule delivery system is intended to improve local drug retention, enhance drug stability, and provide controlled release of triamcinolone acetonide at the postoperative nasal tissues.

Eligible participants will be randomly assigned to receive either topical triamcinolone acetonide-loaded polymeric nanocapsules or standard normal saline nasal irrigation following endoscopic nasal surgery.

Participants will be followed using endoscopic clinical assessments, patient-reported sinonasal symptom questionnaires, evaluation of postoperative complications, and monitoring for local or systemic corticosteroid-related adverse effects.

03

Conditions studied

  • Chronic Rhinosinusitis (CRS)
  • Nasal Polyps
  • Postoperative Healing After Endoscopic Nasal Surgery

Browse trials for

Keywords

  • Triamcinolone acetonide
  • Nanocapsules
  • Polymeric nanocapsules
  • Endoscopic nasal surgery
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 60 years.
  • Patients scheduled to undergo one of the following procedures:
  • Functional endoscopic sinus surgery
  • Endoscopic turbinoplasty
  • Endoscopic septoplasty
  • Diagnosis of chronic rhinosinusitis and/or nasal polyps requiring surgical intervention.
  • Ability and willingness to provide written .
  • Ability and willingness to comply with study treatment and scheduled follow-up visits.

Exclusion criteria

Exclusion Criteria

  • Known to triamcinolone acetonide.
  • Known hypersensitivity to any component of the polymeric nanocapsule formulation.
  • Systemic to therapy.
  • Active severe nasal or sinonasal infection at the time of enrollment or treatment.
  • Pregnancy or breastfeeding, if excluded in the approved protocol.
  • Uncontrolled diabetes mellitus, if corticosteroid exposure is considered .
  • or use of immunosuppressive therapy.
  • Recent use of systemic or intranasal corticosteroids within the protocol-defined .
  • Participation in another clinical trial.
  • Any medical or psychiatric condition that may interfere with , study treatment, or follow-up.
  • Inability to complete the required questionnaires or follow-up visits.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Triamcinolone Acetonide Nanocapsules

    Participants assigned to this arm will receive topical triamcinolone acetonide-loaded polymeric nanocapsules as postoperative nasal therapy following endoscopic nasal surgery

    Drug: Triamcinolone Acetonide-Loaded Polymeric Nanocapsules

  • Active comparator
    Normal Saline Irrigation

    Participants assigned to this arm will receive standard postoperative normal saline nasal irrigation following endoscopic nasal surgery.

    Other: Normal Saline Nasal Irrigation

Interventions

  • DrugTriamcinolone Acetonide-Loaded Polymeric Nanocapsules

    Triamcinolone acetonide incorporated into polymeric nanocapsules prepared using a nanoprecipitation method will be administered topically to the postoperative nasal cavity.

  • OtherNormal Saline Nasal Irrigation

    Participants will receive postoperative nasal irrigation with 0.9% sodium chloride solution.

06

What researchers measure

Primary outcomes

  1. Change in Lund-Kennedy Endoscopic Score

    The Lund-Kennedy Endoscopic Score will be used to assess postoperative nasal mucosal healing and inflammation. The score ranges from 0 to 20 and is calculated by summing the scores for polyps, discharge, oedema, scarring, and crusting (each scored 0-2 on both the left and right sides). A total score of 0 indicates no disease, and a score of 20 indicates the most severe disease. Therefore, higher scores indicate a worse outcome

    Time frame: Baseline, postoperative week 2, postoperative week 4, and postoperative month 3

  2. Change in 22-Item Sinonasal Outcome Test Score (SNOT-22)

    SNOT-22 will be used to assess participant-reported sinonasal symptoms and health-related quality of life. The total score ranges from 0 to 110 and is calculated by summing the scores for 22 individual items. Each item is rated from 0 ("No problem") to 5 ("Problem as bad as it can be"). A total score of 0 indicates no disease burden, and a score of 110 indicates the maximum disease burden. Therefore, higher scores indicate a worse outcome.

    Time frame: Baseline, postoperative week 2, postoperative week 4, and postoperative month 3

Secondary outcomes

  1. Incidence of Postoperative Complications

    The number and percentage of participants experiencing protocol-defined postoperative complications will be recorded.

    Time frame: From the date of surgery through postoperative month 3

  2. Incidence of Corticosteroid-Related Adverse Events

    The number and percentage of participants experiencing local or systemic adverse events considered related to topical triamcinolone acetonide will be recorded.

    Time frame: From the first administration of study treatment through postoperative month 3

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Camargo GDA, Ferreira L, Schebelski DJ, Lyra AM, Barboza FM, Carletto B, Koga AY, Semianko BC, Dias DT, Lipinski LC, Novatski A, Raman V, Manfron J, Nadal JM, Farago PV. Characterization and In Vitro and In Vivo Evaluation of Tacrolimus-Loaded Poly(epsilon-Caprolactone) Nanocapsules for the Management of Atopic Dermatitis. Pharmaceutics. 2021 Nov 26;13(12):2013. doi: 10.3390/pharmaceutics13122013. PubMed 34959295 ↗
  • Erdogar N, Akkin S, Bilensoy E. Nanocapsules for Drug Delivery: An Updated Review of the Last Decade. Recent Pat Drug Deliv Formul. 2018;12(4):252-266. doi: 10.2174/1872211313666190123153711. PubMed 30674269 ↗
  • Kothamasu P, Kanumur H, Ravur N, Maddu C, Parasuramrajam R, Thangavel S. Nanocapsules: the weapons for novel drug delivery systems. Bioimpacts. 2012;2(2):71-81. doi: 10.5681/bi.2012.011. Epub 2012 Apr 5. PubMed 23678444 ↗
  • Siebelt M, Korthagen N, Wei W, Groen H, Bastiaansen-Jenniskens Y, Muller C, Waarsing JH, de Jong M, Weinans H. Triamcinolone acetonide activates an anti-inflammatory and folate receptor-positive macrophage that prevents osteophytosis in vivo. Arthritis Res Ther. 2015 Dec 5;17:352. doi: 10.1186/s13075-015-0865-1. PubMed 26637220 ↗
  • Imai S, Otsuka T, Naito A, Shimazawa M, Hara H. Triamcinolone Acetonide Suppresses Inflammation and Facilitates Vascular Barrier Function in Human Retinal Microvascular Endothelial Cells. Curr Neurovasc Res. 2017;14(3):232-241. doi: 10.2174/1567202614666170619081929. PubMed 28625129 ↗
  • Bugten V, Nordgard S, Steinsvag S. Long-term effects of postoperative measures after sinus surgery. Eur Arch Otorhinolaryngol. 2008 May;265(5):531-7. doi: 10.1007/s00405-007-0501-z. Epub 2007 Oct 25. PubMed 17960410 ↗
  • Eloy P, Andrews P, Poirrier AL. Postoperative care in endoscopic sinus surgery: a critical review. Curr Opin Otolaryngol Head Neck Surg. 2017 Feb;25(1):35-42. doi: 10.1097/MOO.0000000000000332. PubMed 27846022 ↗
  • Rudmik L, Soler ZM, Orlandi RR, Stewart MG, Bhattacharyya N, Kennedy DW, Smith TL. Early postoperative care following endoscopic sinus surgery: an evidence-based review with recommendations. Int Forum Allergy Rhinol. 2011 Nov-Dec;1(6):417-30. doi: 10.1002/alr.20072. Epub 2011 Oct 29. PubMed 22144050 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2027, 12 months after the start.

Of 24 phase 2 interventional studies under Nasal Polyps, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 32. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2026
First posted
Jul 20, 2026
StartActual
May 1, 2026
Primary completionEst.
May 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07714525
Lead sponsor
Deraya University
Responsible party
Sponsor
First posted
Jul 20, 2026
Start date
May 1, 2026
Primary completion
May 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Jul 27, 2026

Study contacts

Sally Mansour Helmy
Contact
aliaa.gamal@deraya.edu.eg
+20 102 692 0921
Aliaa Gamal Hussein
Contact
aliaa.gamal@deraya.edu.eg
+201003041632
Sally Mansour Helmy
principal investigator · Deraya University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion